Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic control mainly by enhancing glucose-dependent insulin secretion. Yet patients may have different responses when treated with GLP-1 RAs. This study investigated whether the baseline β-cell function affects the treatment response to exenatide in patients with newly diagnosed T2D.
Methods: In the CONFIDENCE study, 110 patients with newly diagnosed T2D completed 48-week exenatide treatment. Glucose and insulin during fixed breakfast were measured at baseline and 48 weeks. This post-hoc analysis evaluated the effect of baseline β-cell function represented by the disposition index (DI) on treatment response to exenatide.
Results: The 110 patients were 49.6±10 years old, with the baseline HbA1c of 8.0±1.0% and BMI of 25.9±3.0kg/m2. As shown in Table 1, patients with the lowest tertile DI had the highest HbA1c, FPG, PPG and the worst insulin resistance at baseline. After adjusting for the baseline values, the improvements of glycemic control were similar among all tertiles groups, regardless of baseline DI. The effects of lowering weight or BMI were comparable in all groups on the basis of the balanced baseline values.
Conclusion: In newly diagnosed T2D who have relatively good residual β-cell function, DI at baseline may not predict the treatment response to exenatide both on glycemic control and weight reduction.
C. Wang: None. W. Xu: None. H. Deng: None. B. Lin: None. J. Lv: None. L. Zeng: None. B. Yao: None. J. Weng: None.
National Natural Science Foundation of China (81770821 to W.X.); National Key Research and Development Program of China (2016YFC1304801); Eli Lilly and Company